Guardant Health - GH STOCK NEWS

Guardant Health, Inc. (NASDAQ: GH) will announce its third-quarter financial results on November 4, 2021, post-market. A conference call will follow at 1:30 PM PT / 4:30 PM ET, available via webcast on the company's website. Guardant Health specializes in precision oncology, providing proprietary tests like Guardant360 and Guardant Reveal to enhance cancer care and improve patient outcomes. These tests are integral to their comprehensive oncology platform aimed at reducing healthcare costs and supporting advanced and early-stage cancer patients.

Guardant Health has launched the ORACLE study, a 1,000-patient, multi-center trial aimed at assessing the Guardant Reveal™ test's ability to predict cancer recurrence in 11 solid tumor types. The study will monitor circulating tumor DNA (ctDNA) levels for up to five years. This blood-only liquid biopsy test is designed to improve decision-making for oncologists treating early-stage cancer by identifying patients at risk for recurrence. Guardant Health intends to extend the application of this test beyond colorectal cancer, showcasing its commitment to enhancing patient care.

Guardant Health presented critical findings at the ESMO 2021 congress, revealing the need for improved HER2-directed therapies in metastatic colorectal cancer. Their Guardant360® liquid biopsy test highlighted treatment resistance patterns and molecular targets essential for personalized cancer care. Key studies emphasized the unmet need for effective treatments for HER2+ mCRC patients and provided insights into molecular features in early-onset colorectal cancer. The data underscores the importance of liquid biopsy in enhancing clinical outcomes for advanced cancer patients.

Guardant Health (Nasdaq: GH) will present new data on its Guardant360 liquid biopsy test at the IASLC 2021 World Conference on Lung Cancer, highlighting its advantages in clinical decision-making for advanced lung cancer. The data aims to demonstrate the test's ability to rapidly identify actionable biomarkers, facilitating quicker treatment initiation compared to traditional tissue biopsies. Key presentations include studies on genomic profiling and treatment impact, scheduled from September 8-14, 2021.

Guardant Health, a precision oncology leader, will participate virtually in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 1:15 p.m. PT. Interested individuals can access a live and archived webcast via the company’s website. Guardant Health focuses on cancer care through advanced tests like Guardant360 and Guardant Reveal, aiming to improve patient outcomes and reduce healthcare costs. The company is dedicated to enhancing cancer screening, particularly for asymptomatic individuals.

Guardant Health, a leader in precision oncology, announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10 at 4:00 p.m. PT. The event will feature a fireside chat with the company’s management, accessible via a webcast on their website. Guardant Health specializes in revolutionary cancer testing technologies like Guardant360 and Guardant Reveal, aimed at improving clinical outcomes and reducing costs. Their innovations support comprehensive cancer care and screening programs to help combat cancer globally.

Guardant Health (Nasdaq: GH) has announced a new leadership structure to drive growth, appointing Helmy Eltoukhy and AmirAli Talasaz as co-CEOs. Eltoukhy will also serve as Chairman, while Meghan Joyce joins the Board as an Independent Director. This new structure aims to enhance focus on Oncology and Screening, following recent oncology product launches and a planned blood-based screening LDT in 2022. The leadership team emphasizes a commitment to innovative cancer solutions and improved patient outcomes, positioning Guardant as a potential leader in early cancer detection.

Guardant Health reported a revenue of $92.1 million for Q2 2021, up 39% year-over-year, with clinical testing revenue increasing 54%. The company performed 20,830 clinical tests and 3,653 biopharmaceutical tests. Gross profit rose to $62.2 million with a 68% gross margin. However, operating expenses surged to $159.8 million, driving a net loss of $97.6 million. Guardant maintains its 2021 revenue guidance of $360 million to $370 million, indicating 26% to 29% growth over 2020 amid ongoing COVID-19 uncertainties.

Fight Colorectal Cancer and Guardant Health will honor clinical researchers and advocates with the “Back to Screening Award for Research Advocacy Excellence.” This recognition takes place at the “Path to a Cure” event in December 2021, emphasizing efforts to revitalize colorectal cancer screening post-pandemic. The ECLIPSE trial, evaluating a blood test for colorectal cancer screening, aims for FDA approval. With only 66% of adults screened, the trial addresses a critical healthcare gap exacerbated by COVID-19, reflecting a pressing need for non-invasive solutions to combat rising colorectal cancer rates among younger populations.